GermBullet Flu Remedy Unapproved, Says FDA Warning Letter

Federal regulators are warning the maker of a new cold and flu remedy that marketing claims for the product violate FDA guidelines. 

The Boca Raton, Florida, based company, Flu and Cold Defense LLC, was issued a warning letter by the FDA and Federal Trade Commission (FTC) on January 24, indicating that the company is illegally marketing GermBullet as a cure or treatment for the flu. These claims cause the product to be in violation of the Federal Food, Drug, and Cosmetic Act.

GermBullet was introduced as an inhaled form of flu protection. According to the company website, it is a botanical product with essential oils and wild-grown plant ingredients for the use of preventing germs in association with the flu. It is packaged in a small nasal inhaler bottle to decrease germs “entering through the nose.”

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to the letter, the marketing violates the act in many areas, including the graphics on the website and product labeling, which specifically indicate the product is a cold and flu prevention.

Additionally, the company made claims that GermBullet is laboratory tested and shown to reduce illness-causing bacteria, cold and flu viruses by reducing exposure to germs and illness through its inhaled application.

The advertising claimed the product was tested by an FDA-recognized virology lab which “confirmed” GermBullet’s capability to kill cold and flu viruses. The FDA has not recognized a virology lab that has tested the product, said officials.

The FDA warning letter also noted that the product was fairly new and not recognized as safe and effective for its labeled uses. New drugs must first be approved by the FDA prior to interstate sale.

Another item of concern highlighted in the warning notice detailed the labeling and directions provided for the product were not adequate for persons without medical training to follow correctly, causing the product to be deemed misbranded.

Flu and Cold Defense LLC is required to investigate and identify the violations to prevent recurrences and was given 15 days to notify the FDA of the steps they are taking to correct the violations. Failure to correct the violations may result in legal action, Federal District Court injunction, administrative cease and desist order and seizure. The company may also be liable to pay restitution to consumers for concerning the false advertising claims made.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted 2 days ago)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).